JP2013500729A - フルクトシルアミノ酸オキシダーゼ - Google Patents
フルクトシルアミノ酸オキシダーゼ Download PDFInfo
- Publication number
- JP2013500729A JP2013500729A JP2012523236A JP2012523236A JP2013500729A JP 2013500729 A JP2013500729 A JP 2013500729A JP 2012523236 A JP2012523236 A JP 2012523236A JP 2012523236 A JP2012523236 A JP 2012523236A JP 2013500729 A JP2013500729 A JP 2013500729A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- fructosyl
- oxidase
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010078123 amadoriase Proteins 0.000 title claims abstract description 156
- 230000000694 effects Effects 0.000 claims abstract description 120
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 57
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 57
- 101710088194 Dehydrogenase Proteins 0.000 claims abstract description 45
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 29
- 108091005996 glycated proteins Proteins 0.000 claims abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 72
- 102000004190 Enzymes Human genes 0.000 claims description 46
- 108090000790 Enzymes Proteins 0.000 claims description 46
- JEQHVKBNRPNQDY-UTINFBMNSA-N (2s)-3-methyl-2-[[(3s,4r,5r)-3,4,5,6-tetrahydroxy-2-oxohexyl]amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO JEQHVKBNRPNQDY-UTINFBMNSA-N 0.000 claims description 29
- BNQVUHQWZGTIBX-IUCAKERBSA-N Val-His Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CN=CN1 BNQVUHQWZGTIBX-IUCAKERBSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 16
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 claims description 12
- 108010047495 alanylglycine Proteins 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 230000027756 respiratory electron transport chain Effects 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- XLILXFRAKOYEJX-GUBZILKMSA-N Asp-Leu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLILXFRAKOYEJX-GUBZILKMSA-N 0.000 claims description 8
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 claims description 8
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 claims description 8
- XQNRANMFRPCFFW-GCJQMDKQSA-N Ala-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C)N)O XQNRANMFRPCFFW-GCJQMDKQSA-N 0.000 claims description 7
- MAISCYVJLBBRNU-DCAQKATOSA-N Arg-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N MAISCYVJLBBRNU-DCAQKATOSA-N 0.000 claims description 7
- GHNDBBVSWOWYII-LPEHRKFASA-N Arg-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O GHNDBBVSWOWYII-LPEHRKFASA-N 0.000 claims description 7
- WECYRWOMWSCWNX-XUXIUFHCSA-N Ile-Arg-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O WECYRWOMWSCWNX-XUXIUFHCSA-N 0.000 claims description 7
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 claims description 7
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 claims description 7
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 claims description 7
- 108010000761 leucylarginine Proteins 0.000 claims description 7
- 108010075702 lysyl-valyl-aspartyl-leucine Proteins 0.000 claims description 7
- HYPVLWGNBIYTNA-GUBZILKMSA-N Gln-Leu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HYPVLWGNBIYTNA-GUBZILKMSA-N 0.000 claims description 6
- IRRZDAIFYHNIIN-JYJNAYRXSA-N Lys-Gln-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IRRZDAIFYHNIIN-JYJNAYRXSA-N 0.000 claims description 6
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 claims description 4
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 claims description 4
- VOEGKUNRHYKYSU-XVYDVKMFSA-N His-Asp-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O VOEGKUNRHYKYSU-XVYDVKMFSA-N 0.000 claims description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims description 4
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical group C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 claims description 2
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 claims description 2
- 125000006248 tosyl amino group Chemical group [H]N(*)S(=O)(=O)C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 3
- OOZJHTXCLJUODH-QXEWZRGKSA-N Pro-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 OOZJHTXCLJUODH-QXEWZRGKSA-N 0.000 claims 1
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 claims 1
- SIMKLINEDYOTKL-MBLNEYKQSA-N Thr-His-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C)C(=O)O)N)O SIMKLINEDYOTKL-MBLNEYKQSA-N 0.000 claims 1
- 108010017391 lysylvaline Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 9
- 102220644281 SUMO-activating enzyme subunit 2_N56A_mutation Human genes 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 18
- 229910052760 oxygen Inorganic materials 0.000 description 18
- 239000001301 oxygen Substances 0.000 description 18
- 239000008363 phosphate buffer Substances 0.000 description 17
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 16
- 239000000758 substrate Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 12
- 230000035772 mutation Effects 0.000 description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108010004903 glycosylated serum albumin Proteins 0.000 description 10
- 102220496088 5-hydroxytryptamine receptor 3B_N47A_mutation Human genes 0.000 description 9
- 102220488785 ADP-ribosylation factor 1_N52A_mutation Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000370 acceptor Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- CCBICDLNWJRFPO-UHFFFAOYSA-N 2,6-dichloroindophenol Chemical compound C1=CC(O)=CC=C1N=C1C=C(Cl)C(=O)C(Cl)=C1 CCBICDLNWJRFPO-UHFFFAOYSA-N 0.000 description 7
- 102000003992 Peroxidases Human genes 0.000 description 7
- DPXDJGUFSPAFJZ-UHFFFAOYSA-L disodium;4-[3-methyl-n-(4-sulfonatobutyl)anilino]butane-1-sulfonate Chemical compound [Na+].[Na+].CC1=CC=CC(N(CCCCS([O-])(=O)=O)CCCCS([O-])(=O)=O)=C1 DPXDJGUFSPAFJZ-UHFFFAOYSA-L 0.000 description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 description 7
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 6
- 101000641031 Homo sapiens Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Proteins 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- -1 α-fructosyl amino Chemical group 0.000 description 6
- 238000005571 anion exchange chromatography Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 101710136887 Monomeric sarcosine oxidase Proteins 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 108010040030 histidinoalanine Proteins 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 240000006439 Aspergillus oryzae Species 0.000 description 3
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 3
- DCNMIDLYWOTSGK-HSUXUTPPSA-N D-glucosone Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C=O DCNMIDLYWOTSGK-HSUXUTPPSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 241000736122 Parastagonospora nodorum Species 0.000 description 2
- 241000235061 Pichia sp. Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002907 osmium Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000001008 quinone-imine dye Substances 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- TUUNPXSIKLFRAH-SGPHPBPESA-N (2S)-2,6-diamino-6-[(3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCC(N)C1(CO)O[C@H](CO)[C@@H](O)[C@@H]1O TUUNPXSIKLFRAH-SGPHPBPESA-N 0.000 description 1
- MASUWVVNWALEEM-UHFFFAOYSA-M 1-methoxy-5-methylphenazin-5-ium;methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2N=C3C(OC)=CC=CC3=[N+](C)C2=C1 MASUWVVNWALEEM-UHFFFAOYSA-M 0.000 description 1
- BZDYHKVWLWWTBE-UHFFFAOYSA-N 2-[n-(2-hydroxyethyl)-3-methoxy-2-nitrosoanilino]ethanol;hydrochloride Chemical compound Cl.COC1=CC=CC(N(CCO)CCO)=C1N=O BZDYHKVWLWWTBE-UHFFFAOYSA-N 0.000 description 1
- RLEHYCNEHWSDLS-UHFFFAOYSA-N 2-[n-(2-hydroxyethyl)-4-nitrosoanilino]ethanol Chemical compound OCCN(CCO)C1=CC=C(N=O)C=C1 RLEHYCNEHWSDLS-UHFFFAOYSA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- NLDNNZKUSLAYFW-NHCYSSNCSA-N Asn-Lys-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLDNNZKUSLAYFW-NHCYSSNCSA-N 0.000 description 1
- VHQSGALUSWIYOD-QXEWZRGKSA-N Asn-Pro-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O VHQSGALUSWIYOD-QXEWZRGKSA-N 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000741763 Coniochaeta sp. Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 102220503119 Glypican-2_N56D_mutation Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 102220470904 Interferon-induced protein with tetratricopeptide repeats 5_K48E_mutation Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102220508956 Leucine-rich repeat-containing G-protein coupled receptor 4_N44A_mutation Human genes 0.000 description 1
- IEVXCWPVBYCJRZ-IXOXFDKPSA-N Lys-Thr-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IEVXCWPVBYCJRZ-IXOXFDKPSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000124340 Penicillium terrenum Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical group [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- 241000952055 Ulocladium sp. Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 102220370916 c.136T>G Human genes 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- MWHUIOFIRPAVBJ-UHFFFAOYSA-N n-methyl-n-(2-methylphenyl)nitrous amide Chemical compound O=NN(C)C1=CC=CC=C1C MWHUIOFIRPAVBJ-UHFFFAOYSA-N 0.000 description 1
- KOOMFXGDLMRWSN-UHFFFAOYSA-N n-phenylnitrous amide Chemical compound O=NNC1=CC=CC=C1 KOOMFXGDLMRWSN-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102200161518 rs72554080 Human genes 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012533 structure-function relationship study Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
PnFPOX (61)Val Ser Leu Arg Asn Pro Val Asp Leu Gln Leu Ala(72)(配列番号:13)
FPOX−C (61)Ile Arg Leu Arg Asn Lys Val Asp Leu Gln Met Ser(72)(配列番号:14)
PnFPOX (109)Ser Gly Tyr Gln Ala Leu Val Asp Ala Gly Leu Asp Ala Thr Asn Glu(124)(配列番号:15)
FPOX−C (109)Lys Gln Tyr Gln Ala Leu His Asp Ala Gly Ala Gly Leu Glu Lys Thr His Ala(126)(配列番号:16)
N1−1 FAOD変異体の製造および特徴付
N1−1野生型およびN47A変異体FAODの精製
PnFPOX変異体の製造
PnFPOXN56A変異体の精製
アマドリアーゼII FAOD変異体の製造と特徴付
バイオセンサーの構築
FPOX−C変異体の製造および特徴付
ループ変異体の製造および特徴付
PnFPOX (61)Val Ser Leu Arg Asn Pro Val Asp Leu Gln Leu Ala(72)(配列番号:13)
FPOX−C (61)Ile Arg Leu Arg Asn Lys Val Asp Leu Gln Met Ser(72)(配列番号:14)
PnFPOX (109)Ser Gly Tyr Gln Ala Leu Val Asp Ala Gly Leu Asp Ala Thr Asn Glu(124)(配列番号:15)
FPOX−C (109)Lys Gln Tyr Gln Ala Leu His Asp Ala Gly Ala Gly Leu Glu Lys Thr His Ala(126)(配列番号:16)
Pn FPOX/L1ExC/N56A(すなわち、ループ1領域がFPOX−C由来のループ1領域に置換されているPn FPOXのN56A変異体)
Pn FPOX/L2ExC(すなわち、ループ2領域がFPOX−C由来のループ2領域に置換されているPn FPOX)
Pn FPOX/L2ExC/N56A(すなわち、ループ2領域がFPOX−C由来のループ2領域に置換されているPn FPOXのN56A変異体)
FPOX−C/L1ExPn(すなわち、ループ1領域がPn FPOX由来のループ1領域に置換されているFPOX−C)
FPOX−C/L1ExPn/N56A(すなわち、ループ1領域がPn FPOX由来のループ1領域に置換されているFPOX−CのN56A変異体)
FPOX−C/L2ExPn(すなわち、ループ2領域がPn FPOX由来のループ2領域に置換されているFPOX−C)
FPOX−C/L2ExPn/N56A(すなわち、ループ2領域がPn FPOX由来のループ2領域に置換されているFPOX−CのN56A変異体)
Claims (24)
- 配列番号1記載のアミノ酸配列の56位に対応する位置でアミノ酸残基AsnをAla、Cys、Phe、Met、SerおよびValから選択されるアミノ酸残基で置換することにより改変された変異体フルクトシルアミノ酸オキシダーゼ。
- 野生型フルクトシルアミノ酸オキシダーゼと比較して減少されたオキシダーゼ活性を有し、かつ野生型フルクトシルアミノ酸オキシダーゼと比較して増加したデヒドロゲナーゼ活性を有する請求項1記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 野生型フルクトシルアミノ酸オキシダーゼの30%以下のオキシダーゼ活性を有し、かつ野生型フルクトシルアミノ酸オキシダーゼの50%以上のデヒドロゲナーゼ活性を有する請求項1記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 野生型フルクトシルアミノ酸オキシダーゼと比較して増加したデヒドロゲナーゼ活性を有する請求項1記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号1〜12からなる群より選択されるアミノ酸配列であり、配列番号1記載のアミノ酸配列の56位に対応する位置のアミノ酸残基Asnが、Ala、Cys、Phe、Met、SerおよびValから選択されるアミノ酸残基で置換されているアミノ酸配列を有する請求項1記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号1記載のアミノ酸配列であり、56位のアミノ酸残基Ansが、Ala、Cys、Phe、Met、SerおよびValから選択されるアミノ酸残基で置換されているアミノ酸配列を有する請求項1記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号1の109〜124位でアミノ酸配列:Ser Gly Tyr Gln Ala Leu Val Asp Ala Gly Leu Asp Ala Thr Asn Gluが、配列:Lys Gln Tyr Gln Ala Leu His Asp Ala Gly Ala Gly Leu Glu Lys Thr His Alaに置き換えられている請求項6記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号2記載のアミノ酸配列であり、47位のアミノ酸残基Asnが、Ala、Cys、Phe、Met、SerおよびValから選択されるアミノ酸残基で置換されている請求項1記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号3記載のアミノ酸配列であり、52位のアミノ酸残基Asnが、Ala、Cys、Phe、Met、SerおよびValから選択されるアミノ酸残基で置換されている請求項1記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号7記載のアミノ酸配列であり、56位のアミノ酸残基Asnが、Ala、Cys、Phe、Met、SerおよびValから選択されるアミノ酸残基で置換されている請求項1記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号7の61〜72位でアミノ酸配列:Ile Arg Leu Arg Asn Lys Val Asp Leu Gln Met Serが、配列:Val Ser Leu Arg Asn Pro Val Asp Leu Gln Leu Alaに置き換えられている請求項10記載の変異体フルクトシルアミノ酸オキシダーゼ。
- 請求項1〜11のいずれか1項に記載の変異体フルクトシルアミノ酸オキシダーゼをコードする単離されたポリヌクレオチド。
- 請求項12記載のポリヌクレオチドを含むベクター。
- 請求項13記載のベクターにより形質転換された宿主細胞。
- 試料中の糖化タンパク質をアッセイする方法であって、該試料を請求項1〜11のいずれか1項に記載のフルクトシルアミノ酸オキシダーゼと接触させること、および該フルクトシルアミノ酸オキシダーゼにより酸化された糖化タンパク質の量を測定することを含む方法。
- 試料中のHbA1cを消化してフルクトシルバリンまたはフルクトシルバリルヒスチジンを生成すること、該フルクトシルバリンまたはフルクトシルバリルヒスチジンを請求項1〜11のいずれか1項に記載のフルクトシルアミノ酸オキシダーゼと接触させること、および酸化されたフルクトシルバリンまたはフルクトシルバリルヒスチジンの量を測定することを含むHbA1cをアッセイする方法。
- 試料中のフルクトシルバリン、フルクトシルバリルヒスチジン、HbA1cまたはフルクトシルヘキサペプチドをアッセイするための装置であって、請求項1〜11のいずれか1項に記載のフルクトシルアミノ酸オキシダーゼおよび電子移動メディエーターを含む装置。
- 試料中のフルクトシルバリン、フルクトシルバリルヒスチジン、HbA1cまたはフルクトシルヘキサペプチドをアッセイするためのキットであって、請求項1〜11のいずれか1項に記載のフルクトシルアミノ酸オキシダーゼおよび電子移動メディエーターを含むキット。
- 電極上に固定された請求項1〜11のいずれか1項に記載のフルクトシルアミノ酸オキシダーゼを有する酵素電極。
- フルクトシルバリン、フルクトシルバリルヒスチジン、HbA1cまたはフルクトシルヘキサペプチドをアッセイするための酵素センサーであって、請求項19記載の酵素電極を作用電極として含む酵素センサー。
- 配列番号1記載のアミノ酸配列であり、配列番号1の61〜72位のアミノ酸配列:Val Ser Leu Arg Asn Pro Val Asp Leu Gln Leu Alaが、配列:Ile Arg Leu Arg Asn Lys Val Asp Leu Gln Met Serで置き換えられているアミノ酸配列を有する変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号1記載のアミノ酸配列であり、配列番号1の109〜124位のアミノ酸配列:Ser Gly Tyr Gln Ala Leu Val Asp Ala Gly Leu Asp Ala Thr Asn Gluが、配列:Lys Gln Tyr Gln Ala Leu His Asp Ala Gly Ala Gly Leu Glu Lys Thr His Alaで置き換えられているアミノ酸配列を有する変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号7記載のアミノ酸配列であり、配列番号7の61〜72位のアミノ酸配列:Ile Arg Leu Arg Asn Lys Val Asp Leu Gln Met Serが、配列:Val Ser Leu Arg Asn Pro Val Asp Leu Gln Leu Alaで置き換えられているアミノ酸配列を有する変異体フルクトシルアミノ酸オキシダーゼ。
- 配列番号7記載のアミノ酸配列であり、配列番号1の109〜126位のアミノ酸配列:Lys Gln Tyr Gln Ala Leu His Asp Ala Gly Ala Gly Leu Glu Lys Thr His Alaが、配列:Ser Gly Tyr Gln Ala Leu Val Asp Ala Gly Leu Asp Ala Thr Asn Gluで置き換えられているアミノ酸配列を有する変異体フルクトシルアミノ酸オキシダーゼ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09009969A EP2287295A1 (en) | 2009-08-03 | 2009-08-03 | Mutant Fructosyl amino acid oxidase |
EP09009969.8 | 2009-08-03 | ||
PCT/EP2010/004708 WO2011015326A2 (en) | 2009-08-03 | 2010-08-02 | Fructosyl amino acid oxidase |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013500729A true JP2013500729A (ja) | 2013-01-10 |
JP2013500729A5 JP2013500729A5 (ja) | 2013-09-05 |
JP5897463B2 JP5897463B2 (ja) | 2016-03-30 |
Family
ID=41060017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012523236A Expired - Fee Related JP5897463B2 (ja) | 2009-08-03 | 2010-08-02 | フルクトシルアミノ酸オキシダーゼ |
Country Status (7)
Country | Link |
---|---|
US (1) | US8497083B2 (ja) |
EP (2) | EP2287295A1 (ja) |
JP (1) | JP5897463B2 (ja) |
CN (1) | CN102471763B (ja) |
ES (1) | ES2720287T3 (ja) |
PL (1) | PL2462223T3 (ja) |
WO (1) | WO2011015326A2 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2012018094A1 (ja) * | 2010-08-06 | 2013-10-03 | キッコーマン株式会社 | 基質特異性が改変されたアマドリアーゼ |
WO2015020200A1 (ja) * | 2013-08-09 | 2015-02-12 | キッコーマン株式会社 | 改変型アマドリアーゼ及びその製造法、並びにアマドリアーゼの界面活性剤耐性向上剤及びこれを用いたHbA1c測定用組成物 |
WO2015060431A1 (ja) * | 2013-10-25 | 2015-04-30 | キッコーマン株式会社 | 糖化ペプチドに作用するアマドリアーゼを用いたHbA1c測定法 |
WO2016063984A1 (ja) * | 2014-10-24 | 2016-04-28 | キッコーマン株式会社 | デヒドロゲナーゼ活性の向上したアマドリアーゼ |
WO2016072520A1 (ja) * | 2014-11-07 | 2016-05-12 | キッコーマン株式会社 | アニオン性界面活性剤耐性が向上したアマドリアーゼ |
JP2017049131A (ja) * | 2015-09-02 | 2017-03-09 | 旭化成ファーマ株式会社 | くし型電極を用いた糖化タンパク質の測定方法 |
WO2017183717A1 (ja) * | 2016-04-22 | 2017-10-26 | キッコーマン株式会社 | HbA1cデヒドロゲナーゼ |
JP2021536499A (ja) * | 2018-09-18 | 2021-12-27 | 深セン瑞健生物科技有限公司Shenzhen Ruijian Bioscience Technology Limited Company | 血液脳関門を通過することができるポリペプチド |
WO2023145689A1 (ja) * | 2022-01-27 | 2023-08-03 | 株式会社Provigate | フルクトシルアミノ酸オキシダーゼ、フルクトシルアミノ酸オキシダーゼの製造方法、糖化タンパク質センサ、及び糖化タンパク質の測定方法。 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041715A1 (ja) | 2008-10-09 | 2010-04-15 | 協和メデックス株式会社 | 新規フルクトシルペプチドオキシダーゼ |
CN102171338B (zh) * | 2008-10-10 | 2014-08-13 | 东洋纺织株式会社 | 具有果糖基缬氨酰基组氨酸氧化酶活性的蛋白质及其修饰产物以及其应用 |
US9708586B2 (en) | 2010-08-06 | 2017-07-18 | Kikkoman Corporation | Amadoriase having altered substrate specificity |
JPWO2012043601A1 (ja) * | 2010-09-29 | 2014-02-24 | キッコーマン株式会社 | アマドリアーゼ改変体 |
WO2013100006A1 (ja) | 2011-12-28 | 2013-07-04 | キッコーマン株式会社 | 熱安定性が向上したアマドリアーゼ、その遺伝子および組換えdnaならびに熱安定性が向上したアマドリアーゼの製造法 |
EP2843050B1 (en) * | 2012-04-27 | 2019-03-13 | Kikkoman Corporation | Modified amadoriase capable of acting on fructosyl hexapeptide |
JP6363327B2 (ja) * | 2013-03-25 | 2018-07-25 | キッコーマン株式会社 | 改変アマドリアーゼ |
CN105683374A (zh) | 2013-10-25 | 2016-06-15 | 龟甲万株式会社 | 血红蛋白A1c的测定方法和测定试剂盒 |
CN103695380B (zh) * | 2013-12-27 | 2016-05-25 | 宁波美康生物科技股份有限公司 | 果糖氨基酸氧化酶、制备方法及含该酶的糖化白蛋白检测试剂盒 |
TWI668229B (zh) | 2016-12-13 | 2019-08-11 | 財團法人工業技術研究院 | 重組蛋白質及其製造方法與應用 |
CN110520728B (zh) * | 2017-03-03 | 2022-12-06 | 聚合物技术系统公司 | 用于酶促a1c检测和定量的系统和方法 |
US11703513B2 (en) | 2017-08-07 | 2023-07-18 | Polymer Technology Systems, Inc. | Systems and methods for enzymatic A1C detection and quantification |
WO2020264347A1 (en) * | 2019-06-26 | 2020-12-30 | Polymer Technology Systems, Inc. | Systems and methods for reduction of oxygen tension in electrochemical biosensors |
CN111676236A (zh) * | 2020-03-12 | 2020-09-18 | 北京达成生物科技有限公司 | 一种重组flod蛋白的大肠杆菌表达方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010104278A (ja) * | 2008-10-29 | 2010-05-13 | Toyobo Co Ltd | フルクトシルアミノ酸測定用酵素、およびその利用法 |
JP2010148358A (ja) * | 2008-12-23 | 2010-07-08 | Toyobo Co Ltd | フルクトシル−l−バリルヒスチジン測定用酵素、およびその利用法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0665300B2 (ja) | 1985-05-22 | 1994-08-24 | 財団法人野田産業科学研究所 | フルクトシルアミノ酸オキシダーゼ |
JPS61280297A (ja) | 1985-06-04 | 1986-12-10 | Noda Sangyo Kagaku Kenkyusho | アマドリ化合物の定量法及びその定量用試薬 |
DE3826922A1 (de) | 1988-08-09 | 1990-02-22 | Boehringer Mannheim Gmbh | Verfahren zur kolorimetrischen bestimmung eines analyten mittels enzymatischer oxidation |
JP2601356B2 (ja) | 1989-11-14 | 1997-04-16 | 財団法人野田産業科学研究所 | フルクトシルアミン・オキシダーゼ、その製造法、該酵素を用いたアマドリ化合物の定量法及びその試薬 |
GB9116315D0 (en) | 1991-07-29 | 1991-09-11 | Genzyme Ltd | Assay |
JP2923222B2 (ja) | 1994-03-03 | 1999-07-26 | 株式会社京都第一科学 | フルクトシルアミノ酸オキシダーゼ及びその製造方法 |
JP3850904B2 (ja) | 1994-10-05 | 2006-11-29 | アークレイ株式会社 | フルクトシルアミノ酸オキシダーゼ及びその製造方法 |
DE19629656A1 (de) | 1996-07-23 | 1998-01-29 | Boehringer Mannheim Gmbh | Diagnostischer Testträger mit mehrschichtigem Testfeld und Verfahren zur Bestimmung von Analyt mit dessen Hilfe |
DE19753847A1 (de) | 1997-12-04 | 1999-06-10 | Roche Diagnostics Gmbh | Analytisches Testelement mit Kapillarkanal |
US5997817A (en) | 1997-12-05 | 1999-12-07 | Roche Diagnostics Corporation | Electrochemical biosensor test strip |
JP3949854B2 (ja) | 1999-10-01 | 2007-07-25 | キッコーマン株式会社 | 糖化蛋白質の測定方法 |
JP2003079386A (ja) | 2001-06-29 | 2003-03-18 | Kikkoman Corp | 新規なフルクトシルアミノ酸オキシダーゼ |
JP4231668B2 (ja) * | 2001-09-04 | 2009-03-04 | キッコーマン株式会社 | 新規なフルクトシルペプチドオキシダーゼ |
CN1823166B (zh) * | 2003-05-21 | 2012-06-13 | 旭化成制药株式会社 | 血红蛋白a1c的测定方法和用于此目的的酶及其生产方法 |
WO2004113901A1 (en) | 2003-06-20 | 2004-12-29 | Roche Diagnostics Gmbh | Test strip with slot vent opening |
US8003359B2 (en) * | 2006-04-25 | 2011-08-23 | Kikkoman Corporation | Eukaryotic amadoriase having excellent thermal stability, gene and recombinant DNA for the eukaryotic amadoriase, and process for production of eukaryotic amadoriase having excellent thermal stability |
-
2009
- 2009-08-03 EP EP09009969A patent/EP2287295A1/en not_active Withdrawn
-
2010
- 2010-08-02 ES ES10742433T patent/ES2720287T3/es active Active
- 2010-08-02 PL PL10742433T patent/PL2462223T3/pl unknown
- 2010-08-02 WO PCT/EP2010/004708 patent/WO2011015326A2/en active Application Filing
- 2010-08-02 CN CN201080034342.5A patent/CN102471763B/zh not_active Expired - Fee Related
- 2010-08-02 JP JP2012523236A patent/JP5897463B2/ja not_active Expired - Fee Related
- 2010-08-02 EP EP10742433.5A patent/EP2462223B1/en active Active
-
2012
- 2012-02-03 US US13/365,487 patent/US8497083B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010104278A (ja) * | 2008-10-29 | 2010-05-13 | Toyobo Co Ltd | フルクトシルアミノ酸測定用酵素、およびその利用法 |
JP2010148358A (ja) * | 2008-12-23 | 2010-07-08 | Toyobo Co Ltd | フルクトシル−l−バリルヒスチジン測定用酵素、およびその利用法 |
Non-Patent Citations (4)
Title |
---|
JPN6014047575; Foster, S.J. et al.: 'Accession No.ACB30148, Definition: fructosyl-amino acid oxidase [Epichloe festucae].' Database DDBJ/EMBL/Genbank[online] , 20080329 * |
JPN6014047577; Birren,B. et al.: 'Accession No.XP_001932041, Diffinition: fructosyl amino acid oxidase [Pyrenophora tritici-repentis P' Database DDBJ/EMBL/Genbank [online] , 20080530 * |
JPN6014047578; Biosci. Biotechnol. Biochem. Vol.66, No.6, 2002, pp.1256-1261 * |
JPN6014047580; SCIENCE Vol.294, No.5550, 2001, pp.2317-2323 * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2012018094A1 (ja) * | 2010-08-06 | 2013-10-03 | キッコーマン株式会社 | 基質特異性が改変されたアマドリアーゼ |
JPWO2015020200A1 (ja) * | 2013-08-09 | 2017-03-02 | キッコーマン株式会社 | 改変型アマドリアーゼ及びその製造法、並びにアマドリアーゼの界面活性剤耐性向上剤及びこれを用いたHbA1c測定用組成物 |
WO2015020200A1 (ja) * | 2013-08-09 | 2015-02-12 | キッコーマン株式会社 | 改変型アマドリアーゼ及びその製造法、並びにアマドリアーゼの界面活性剤耐性向上剤及びこれを用いたHbA1c測定用組成物 |
US10619183B2 (en) | 2013-08-09 | 2020-04-14 | Kikkoman Corporation | Modified amadoriase and method for producing the same, agent for improving surfactant resistance of amadoriase and composition for measuring HbA1c using the same |
US11549134B2 (en) | 2013-08-09 | 2023-01-10 | Kikkoman Corporation | Modified amadoriase and method for producing the same, agent for improving surfactant resistance of amadoriase and composition for measuring HbA1c using the same |
KR20160068966A (ko) * | 2013-10-25 | 2016-06-15 | 기꼬만 가부시키가이샤 | 당화 펩티드에 작용하는 아마도리아제를 이용한 HbA1c 측정법 |
WO2015060431A1 (ja) * | 2013-10-25 | 2015-04-30 | キッコーマン株式会社 | 糖化ペプチドに作用するアマドリアーゼを用いたHbA1c測定法 |
JPWO2015060431A1 (ja) * | 2013-10-25 | 2017-03-09 | キッコーマン株式会社 | 糖化ペプチドに作用するアマドリアーゼを用いたHbA1c測定法 |
JP2020141690A (ja) * | 2013-10-25 | 2020-09-10 | キッコーマン株式会社 | 糖化ペプチドに作用するアマドリアーゼを用いたHbA1c測定法 |
KR102390400B1 (ko) | 2013-10-25 | 2022-04-25 | 기꼬만 가부시키가이샤 | 당화 펩티드에 작용하는 아마도리아제를 이용한 HbA1c 측정법 |
US10697979B2 (en) | 2013-10-25 | 2020-06-30 | Kikkoman Corporation | Method for measurement of HbA1c using amadoriase that reacts with glycated peptide |
WO2016063984A1 (ja) * | 2014-10-24 | 2016-04-28 | キッコーマン株式会社 | デヒドロゲナーゼ活性の向上したアマドリアーゼ |
US11499143B2 (en) | 2014-10-24 | 2022-11-15 | Kikkoman Corporation | Amadoriase having enhanced dehydrogenase activity |
JPWO2016063984A1 (ja) * | 2014-10-24 | 2017-08-03 | キッコーマン株式会社 | デヒドロゲナーゼ活性の向上したアマドリアーゼ |
KR20170054475A (ko) | 2014-10-24 | 2017-05-17 | 기꼬만 가부시키가이샤 | 디히드로게나아제 활성이 향상된 아마도리아제 |
EP3786291A1 (en) | 2014-10-24 | 2021-03-03 | Kikkoman Corporation | Amadoriase having enhanced dehydrogenase activity |
JPWO2016072520A1 (ja) * | 2014-11-07 | 2017-08-17 | キッコーマン株式会社 | アニオン性界面活性剤耐性が向上したアマドリアーゼ |
JP2022119761A (ja) * | 2014-11-07 | 2022-08-17 | キッコーマン株式会社 | アニオン性界面活性剤耐性が向上したアマドリアーゼ |
WO2016072520A1 (ja) * | 2014-11-07 | 2016-05-12 | キッコーマン株式会社 | アニオン性界面活性剤耐性が向上したアマドリアーゼ |
JP7094655B2 (ja) | 2014-11-07 | 2022-07-04 | キッコーマン株式会社 | アニオン性界面活性剤耐性が向上したアマドリアーゼ |
US11198852B2 (en) | 2014-11-07 | 2021-12-14 | Kikkoman Corporation | Amadoriase having enhanced anionic surfactant tolerance |
JP2017049131A (ja) * | 2015-09-02 | 2017-03-09 | 旭化成ファーマ株式会社 | くし型電極を用いた糖化タンパク質の測定方法 |
US11262345B2 (en) | 2015-09-02 | 2022-03-01 | Ultizyme International Ltd. | Method for measuring glycated protein using interdigitated electrode |
WO2017038956A1 (ja) * | 2015-09-02 | 2017-03-09 | 有限会社アルティザイム・インターナショナル | くし型電極を用いた糖化タンパク質の測定方法 |
JP2022081510A (ja) * | 2016-04-22 | 2022-05-31 | キッコーマン株式会社 | HbA1cデヒドロゲナーゼ |
US11111517B2 (en) | 2016-04-22 | 2021-09-07 | Kikkoman Corporation | HbA1c dehydrogenase |
JPWO2017183717A1 (ja) * | 2016-04-22 | 2019-02-28 | キッコーマン株式会社 | HbA1cデヒドロゲナーゼ |
WO2017183717A1 (ja) * | 2016-04-22 | 2017-10-26 | キッコーマン株式会社 | HbA1cデヒドロゲナーゼ |
JP7471772B2 (ja) | 2016-04-22 | 2024-04-22 | キッコーマン株式会社 | HbA1cデヒドロゲナーゼ |
JP7487244B2 (ja) | 2016-04-22 | 2024-05-20 | キッコーマン株式会社 | HbA1cデヒドロゲナーゼ |
JP2021536499A (ja) * | 2018-09-18 | 2021-12-27 | 深セン瑞健生物科技有限公司Shenzhen Ruijian Bioscience Technology Limited Company | 血液脳関門を通過することができるポリペプチド |
WO2023145689A1 (ja) * | 2022-01-27 | 2023-08-03 | 株式会社Provigate | フルクトシルアミノ酸オキシダーゼ、フルクトシルアミノ酸オキシダーゼの製造方法、糖化タンパク質センサ、及び糖化タンパク質の測定方法。 |
Also Published As
Publication number | Publication date |
---|---|
WO2011015326A3 (en) | 2011-07-07 |
EP2462223A2 (en) | 2012-06-13 |
CN102471763A (zh) | 2012-05-23 |
WO2011015326A2 (en) | 2011-02-10 |
PL2462223T3 (pl) | 2019-07-31 |
WO2011015326A8 (en) | 2012-02-23 |
EP2287295A1 (en) | 2011-02-23 |
EP2462223B1 (en) | 2019-02-13 |
ES2720287T3 (es) | 2019-07-19 |
CN102471763B (zh) | 2014-07-09 |
US20120208226A1 (en) | 2012-08-16 |
US8497083B2 (en) | 2013-07-30 |
JP5897463B2 (ja) | 2016-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5897463B2 (ja) | フルクトシルアミノ酸オキシダーゼ | |
JP5870027B2 (ja) | フルクトシルペプチジルオキシダーゼおよび糖化タンパク質アッセイ用センサー | |
US8999691B2 (en) | Glucose dehydrogenase | |
US8999140B2 (en) | Glucose oxidase mutants, compositions, devices, kits and uses thereof | |
EP2562250A1 (en) | Glucose oxidase | |
US11499143B2 (en) | Amadoriase having enhanced dehydrogenase activity | |
EP2562251B1 (en) | Cholesterol oxidase | |
US11649440B2 (en) | Thermostabilized Amadoriases and uses thereof | |
JP5036550B2 (ja) | フルクトシルアミン酸化酵素 | |
JPWO2020122231A1 (ja) | エタノールアミンリン酸の定量方法、定量用のオキシドレダクターゼ、定量用組成物、定量用キット及び定量用センサー |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130716 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130716 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151013 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160209 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160302 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5897463 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |